Patricia Inácio, PhD,  science writer—

Sleep problems are common in primary Sjogren’s syndrome patients and seem to worsen symptoms of fatigue and pain, affecting the ability of patients to perform daily activities, according to researchers from the U.K. But a focus group study reports Sjogren’s patients are generally open to tailored sleep therapy interventions as…

In rare cases, patients with Sjögren’s syndrome may develop an unusual degradation of the kidney’s filtering system — a condition called fibrillary glomerulonephritis — a case report shows. While this is only the third case describing this association, the study adds Sjögren’s to the list of disorders linked to fibrillary…

Wize Pharma has enrolled the first participant in a Phase 4 clinical trial investigating the company’s LO2A drops to prevent the dry eye seen in Sjogren’s syndrome. The trial (NCT03319420) in Israel will compare LO2A’s ability to relieve dry eyes with that of an over-the-counter treatment known as Systane…

A history of infection with nontuberculous mycobacteria — linked to chronic pulmonary infections, but unable to cause tuberculosis — may increase the risk for primary Sjögren’s syndrome, according to a large nationwide Taiwanese study. “Although the exact disease mechanism behind [Sjögren’s syndrome] remains elusive, a variety of environmental, genetic and hormonal…

Treatment with epratuzumab, a B-cell targeting antibody, improves clinical outcomes of systemic lupus erythematosus (SLE) in patients with associated Sjögren’s syndrome, research shows. But the post hoc analysis of the Phase 3 EMBODY trials suggests that the treatment fails in those with SLE alone. A post hoc analysis is one that…

A Phase 2 clinical trial testing the efficacy and safety of three investigational therapies — filgotinib, GS-9876, and tirabrutinib  — in adults with active Sjögren’s syndrome is recruiting participants. The study (NCT03100942) is being conducted by Gilead Sciences, in collaboration with Galapagos. It is expected to enroll 140 patients with active Sjögren’s…

Patients with an underlying rheumatic disease, including Sjogren’s syndrome, are not at higher risk for adverse effects when receiving cancer immunotherapies – called immune checkpoint inhibitors – than the rest of the population, according to the results of a Mayo Clinic study. The report, “Cancer immunotherapy in patients…

Women with Sjögren syndrome show particularly high levels of hearing loss and language recognition impairments compared to healthy women or those with rheumatoid arthritis (RA), study reports. The research, “Early hearing loss detection in rheumatoid arthritis and primary Sjögren syndrome using extended high frequency audiometry,” was published in the…